Micro
Emerging
Active
MDCXW FDA-Fortschritt und Ausweitung des klinischen Ausblicks
Neue Erzählung mit begrenzter Abdeckung – noch in der Entstehung.
Score
0,5
Dynamik
▲ 0,0
Artikel
1
Quellen
1
Sentiment-Zeitachse
Ereignis-Zeitachse
Mai 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Hypothesen
Pending
Fälligkeit: 18. Juli 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Fälligkeit: 15. November 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Fälligkeit: 17. August 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Zeitverlauf
Zuletzt aktualisiertMai 19, 2026